Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
snx-5422
- Development stage
- Phase 2
- Lead developer
- Esanex
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
SNX-5422 is a synthetic small molecule inhibitor of heat shock protein 90 (Hsp90), developed as an orally bioavailable prodrug of SNX-2112. It demonstrates strong efficacy and tolerability in preclinical models and has been investigated for its potential antineoplastic activity across a broad range of human cancer cell lines. The drug causes degradation of important Hsp90 client proteins and exhibits potent antiproliferative effects in various cancer types.
- Other names
- 908115-27-5BF52J69Q8TBF-52J69Q8TBF 52J69Q8TDTXSID50238270DTXSID-50238270DTXSID 50238270Glycine, trans-4-((2-(aminocarbonyl)-5-(4,5,6,7-tetrahydro-6,6-dimethyl-4-oxo-3-(trifluoromethyl)-1H-indazol-1-yl)phenyl)amino)cyclohexyl ester
02
Targets
HSP90B1 (GRP94)HSP90 (Heat shock protein 90 chaperone complex)TRAP1 (Tumor necrosis factor receptor-associated protein 1)HSP90AA1 (Heat shock protein HSP90-alpha)
Beyond the preview
Go deeper on snx-5422.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on snx-5422.